NO20031484D0 - Splitt kappe virus preparat - Google Patents

Splitt kappe virus preparat

Info

Publication number
NO20031484D0
NO20031484D0 NO20031484A NO20031484A NO20031484D0 NO 20031484 D0 NO20031484 D0 NO 20031484D0 NO 20031484 A NO20031484 A NO 20031484A NO 20031484 A NO20031484 A NO 20031484A NO 20031484 D0 NO20031484 D0 NO 20031484D0
Authority
NO
Norway
Prior art keywords
split
virus preparation
mantle
mantle virus
preparation
Prior art date
Application number
NO20031484A
Other languages
English (en)
Other versions
NO20031484L (no
Inventor
Brigitte Desiree Alberte Colau
Marguerite Deschamps
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0024088A external-priority patent/GB0024088D0/en
Priority claimed from GB0109288A external-priority patent/GB0109288D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20031484D0 publication Critical patent/NO20031484D0/no
Publication of NO20031484L publication Critical patent/NO20031484L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18563—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18661—Methods of inactivation or attenuation
    • C12N2760/18663—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20031484A 2000-10-02 2003-04-01 Splitt kappe virus preparat NO20031484L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0024088A GB0024088D0 (en) 2000-10-02 2000-10-02 Novel compounds
GB0109288A GB0109288D0 (en) 2001-04-12 2001-04-12 Novel compounds
PCT/EP2001/011328 WO2002028426A1 (en) 2000-10-02 2001-10-01 Split enveloped virus preparation

Publications (2)

Publication Number Publication Date
NO20031484D0 true NO20031484D0 (no) 2003-04-01
NO20031484L NO20031484L (no) 2003-05-28

Family

ID=26245086

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031484A NO20031484L (no) 2000-10-02 2003-04-01 Splitt kappe virus preparat

Country Status (17)

Country Link
US (1) US20040028698A1 (no)
EP (1) EP1322329A1 (no)
JP (1) JP2004510747A (no)
KR (1) KR20030055275A (no)
CN (1) CN1253207C (no)
AR (1) AR030829A1 (no)
AU (2) AU1591402A (no)
BR (1) BR0114392A (no)
CA (1) CA2423610A1 (no)
CZ (1) CZ2003930A3 (no)
HU (1) HUP0302636A3 (no)
IL (1) IL155073A0 (no)
MX (1) MXPA03002890A (no)
NO (1) NO20031484L (no)
NZ (1) NZ525076A (no)
PL (1) PL362964A1 (no)
WO (1) WO2002028426A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2244946C (en) * 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
MXPA03002890A (es) * 2000-10-02 2004-12-03 Glaxosmithkline Biolog Sa Preparacion de virus con envolvente dividido.
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US7588774B2 (en) 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
CN1305526C (zh) * 2003-12-29 2007-03-21 薛平 乙型脑炎病毒裂解疫苗及其制备方法
JP2008531581A (ja) * 2005-02-23 2008-08-14 ユーエービー リサーチ ファウンデーション アルキル−グリコシドで増強されたワクチン接種
WO2007015441A1 (ja) 2005-08-01 2007-02-08 Hisamitsu Pharmaceutical Co., Inc. 経皮または経粘膜投与のためのアジュバントおよび製剤
AU2007209104B2 (en) * 2006-01-26 2010-04-08 Zoetis Services Llc Novel glycolipid adjuvant compositions
GB0622282D0 (en) * 2006-11-08 2006-12-20 Novartis Ag Quality control methods
JP5275047B2 (ja) * 2007-01-31 2013-08-28 久光製薬株式会社 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
AU2009333484B2 (en) 2008-12-09 2014-12-11 Novavax, Inc. Modified RSV F proteins and methods of their use
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
US20130236496A1 (en) * 2010-06-29 2013-09-12 Universite De Laval Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-i-like receptor ligand, or a nod-like receptor ligand to enhance the innate immune response
EA201391515A1 (ru) * 2011-05-26 2014-05-30 Глаксосмитклайн Байлоджикалс С.А. Инактивированная вакцина вируса денге
WO2015064710A1 (ja) 2013-10-31 2015-05-07 久光製薬株式会社 アジュバント組成物、これを含むアジュバント製剤、及びキット
US20160287693A1 (en) 2013-11-15 2016-10-06 Novartis Ag Removal of residual cell culture impurities
FR3025107B1 (fr) 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
CN108697790B (zh) 2015-09-03 2022-02-18 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
AU2019238171A1 (en) 2018-03-19 2020-09-24 Novavax, Inc. Multivalent influenza nanoparticle vaccines
US11576960B2 (en) 2018-03-30 2023-02-14 Georgia State University Research Foundation, Inc. Respiratory syncytial virus (RSV) vaccines
CN110665002B (zh) * 2019-10-29 2023-01-24 信阳市动物疫病预防控制中心 一种用于防治牛病毒性腹泻的抗体制剂及其制备方法
CN113804593B (zh) * 2020-06-11 2024-05-24 北京科兴生物制品有限公司 一种裂解疫苗裂解效果的检测方法及应用
WO2022003565A1 (en) * 2020-07-01 2022-01-06 Medimmune, Llc Detergent and method for purifying a biotherapeutic
CN112190705A (zh) * 2020-09-25 2021-01-08 广州源博医药科技有限公司 一种rsv-sh亚单位疫苗及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1486557A (en) * 1973-10-18 1977-09-21 Flockhart & Co Process for the preparation of pyrogen-free sub-unit vaccine
DE2829089A1 (de) * 1977-07-13 1979-02-01 Sandoz Ag Subunit-vakzine
DE2750045A1 (de) * 1977-11-09 1979-05-10 Behringwerke Ag Verfahren zur entfernung von detergentien aus virusantigensuspensionen
FR2475572A1 (fr) * 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
AT405939B (de) * 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
BR9909915A (pt) * 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
JP2003531866A (ja) * 2000-05-03 2003-10-28 メディミューン，インコーポレイテッド 抗体を用いた呼吸器疾患の組合せ治療法
MXPA03002890A (es) * 2000-10-02 2004-12-03 Glaxosmithkline Biolog Sa Preparacion de virus con envolvente dividido.

Also Published As

Publication number Publication date
NO20031484L (no) 2003-05-28
KR20030055275A (ko) 2003-07-02
HUP0302636A3 (en) 2008-03-28
NZ525076A (en) 2004-09-24
CN1253207C (zh) 2006-04-26
AU1591402A (en) 2002-04-15
JP2004510747A (ja) 2004-04-08
EP1322329A1 (en) 2003-07-02
CA2423610A1 (en) 2002-04-11
PL362964A1 (en) 2004-11-02
AU2002215914B2 (en) 2004-08-19
HUP0302636A2 (hu) 2003-11-28
CZ2003930A3 (cs) 2003-08-13
US20040028698A1 (en) 2004-02-12
AR030829A1 (es) 2003-09-03
WO2002028426A8 (en) 2002-06-06
CN1477973A (zh) 2004-02-25
IL155073A0 (en) 2003-10-31
BR0114392A (pt) 2003-09-02
WO2002028426A1 (en) 2002-04-11
MXPA03002890A (es) 2004-12-03

Similar Documents

Publication Publication Date Title
NO20031484D0 (no) Splitt kappe virus preparat
DE60126045D1 (de) Kompressionsmanschette
DE60114785D1 (de) Einführungshülse
ATE434092T1 (de) Gebäude
NO20031483L (no) Vaksine
DK1226127T3 (da) Substituerede phenylsulfamoylcarboxamider
DE60114153D1 (de) Substituierte arylpyrazine
NO20024172L (no) Vaksine
AR028393A1 (es) Iminoazidas substituidas
ID30187A (id) Dongkrak jenis pantagraf
DE60125415D1 (de) Formeinsatz
EE200200420A (et) Linesoliid - kristallivorm II
NO20030917D0 (no) Anvendelse
NO20030239L (no) Modifisert virus
DE50108881D1 (de) Dimmer
ATE365721T1 (de) Substituierte benzoylcyclohexenone
AR028302A1 (es) Feniluracilos substituidos
FR2816486B1 (fr) Bague
NO20023392D0 (no) Preparat
DE60007360T2 (de) Amorphe modifikation von torasemid
DE50006201D1 (de) Bohle
ATA78799A (de) Feststoffbrenner
UA4234S (uk) Горшок
DK1335938T3 (da) Apolipoprotein-konstruktion
UA4485S (uk) Довідник

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application